Novartis’ IL-17 inhibitor Cosentyx has become the first new biological therapy for the painful skin condition hidradenitis suppurativa (HS) in nearly a decade, following its approval by the European ...

Studies showing significant improvements in scalp hair coverage support the application for approval for adolescents and adults with severe alopecia areata.

AbbVie files for the FDA approval of Rinvoq in alopecia areata, backed by phase III data showing strong hair regrowth and ...

European Commission approves Novartis Rhapsido for CSU in adult patients with inadequate response to H1-antihistamine treatment: Basel Tuesday, April 28, 2026, 09:00 Hrs [IST] Nov ...

Total revenue of $1.27 billion and total net sales of $1.10 billion in the first quarter of 2026, an increase of 21% and 20% ...

Incyte’s povorcitinib has scored a pair of phase 3 wins for a skin condition, although analysts noted the oral JAK inhibitor ...

Incyte Corp (INCY) reports a robust start to 2026 with a 21% revenue increase and advances in its late-stage pipeline, despite challenges in diversifying beyond Jakafi.

Discover how smoking actively sabotages your skin, leading to a specific type of adult acne known as 'Smoker's Acne.' This ...

Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β ...

MSD's confidence in its anti-TL1A antibody tulisokibart in inflammatory diseases has been made apparent by a decision to start trials of the drug in three more indications. Already in phase 3 testing ...

For many patients without a primary care provider, a dermatologist may be the only healthcare professional who can counsel ...

CSU affects nearly 4 million people in Europe; more than 50% continue to experience debilitating symptoms after conventional antihistamine therapy 3-5 Basel, April 27, 2026 – Novartis announced today ...